ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Exploring the anticancer potential of epigallocatechin gallate-loaded sodium alginate nanoparticles: impact of size variation on head and neck cancer cells.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent advances in tumor targeted polymeric nanoparticles for HNC treatment: Enhancing therapeutic efficacy via engineered and biocompatible drug delivery systems.Journal of oral biology and craniofacial researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionHead and neck cancer is a common malignancy, and its current treatments face major challenges, including recurrence, drug resistance, side effects, and high costs. Epigallocatechin gallate (EGCG) from green tea has anticancer properties, but its low stability and bioavailability limit its clinical use. These limitations may be addressed by nanocarrier-based delivery systems.
methodsFive different sizes of sodium alginate (SA) nanoparticles (NPs) were synthesized, and EGCG was loaded into the selected particles. Characterizations of SA NPs with and without EGCG were conducted using dynamic light scattering (DLS), field emission scanning electron microscopy (FE-SEM), and Fourier transform infrared spectroscopy (FTIR). Furthermore, loading capacity, entrapment efficiency, and release profile of the EGCG-loaded NPs were evaluated. The cytotoxicity and cell viability were assessed (MTT and LDH) on TSCC-1 cancer cells. Moreover, cellular uptake, wound healing, colony formation, and apoptosis were also tested.
resultsThe characterizations of NPs confirmed the successful synthesis of SA NPs. Two NP sizes (type 1 and type 4) were selected for EGCG loading, for which the drug release was around 39% for type 1 and 51% for type 4 NPs after 14 days. The optimal cytotoxicity on cancer cells was observed at a concentration of 80 µg/mL of NPs (type 1). A significant reduction in colony numbers was observed after treatment with these EGCG-loaded NPs compared to controls. Furthermore, the EGCG-loaded NPs could prevent cancer cell migration, with an increase in apoptosis levels in TSCC-1 cells treated with type 1 NPs (80 µg/mL).
conclusionIt was demonstrated that EGCG-loaded SA NPs effectively inhibit the proliferation and migration and induce apoptosis in head and neck cancer cells.
Indexed as
Identifiers
41814097What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.